Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.
NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.
